Zhiqiang Qin
Concepts (329)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Herpesvirus 8, Human | 43 | 2024 | 91 | 19.010 |
Why?
| Sarcoma, Kaposi | 27 | 2023 | 72 | 12.770 |
Why?
| Lymphoma, Primary Effusion | 12 | 2023 | 18 | 5.910 |
Why?
| Virus Activation | 7 | 2022 | 32 | 3.930 |
Why?
| Endogenous Retroviruses | 4 | 2024 | 8 | 3.440 |
Why?
| Coinfection | 5 | 2024 | 38 | 3.040 |
Why?
| Host-Pathogen Interactions | 8 | 2020 | 129 | 2.330 |
Why?
| Oncogenic Viruses | 4 | 2021 | 17 | 2.170 |
Why?
| MicroRNAs | 12 | 2020 | 354 | 2.090 |
Why?
| Pyridines | 5 | 2018 | 130 | 2.040 |
Why?
| Mouth | 4 | 2020 | 33 | 1.970 |
Why?
| Viral Proteins | 8 | 2021 | 155 | 1.890 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2018 | 21 | 1.830 |
Why?
| HIV Infections | 6 | 2020 | 354 | 1.770 |
Why?
| Gene Expression Regulation, Viral | 9 | 2020 | 48 | 1.750 |
Why?
| Herpesviridae Infections | 6 | 2021 | 46 | 1.710 |
Why?
| Adamantane | 4 | 2018 | 25 | 1.670 |
Why?
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 829 | 1.660 |
Why?
| Signal Transduction | 13 | 2022 | 1617 | 1.650 |
Why?
| Lung Neoplasms | 5 | 2022 | 605 | 1.640 |
Why?
| Virus Latency | 8 | 2023 | 47 | 1.640 |
Why?
| Ceramides | 4 | 2020 | 28 | 1.610 |
Why?
| Humans | 71 | 2024 | 49827 | 1.610 |
Why?
| Gene Expression Regulation | 7 | 2019 | 979 | 1.600 |
Why?
| Schistosomiasis japonica | 2 | 2023 | 2 | 1.580 |
Why?
| Cell Line, Tumor | 16 | 2023 | 1402 | 1.500 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 152 | 1.460 |
Why?
| Autoantibodies | 4 | 2023 | 116 | 1.460 |
Why?
| Neoplasms | 3 | 2024 | 1233 | 1.390 |
Why?
| Amino Acid Transport System y+ | 3 | 2015 | 3 | 1.350 |
Why?
| Antiviral Agents | 2 | 2021 | 174 | 1.310 |
Why?
| Papillomavirus Infections | 2 | 2024 | 155 | 1.300 |
Why?
| Lymphoma | 3 | 2019 | 65 | 1.290 |
Why?
| Proto-Oncogene Proteins c-met | 3 | 2017 | 20 | 1.240 |
Why?
| Uterine Cervical Neoplasms | 2 | 2024 | 274 | 1.220 |
Why?
| Apoptosis | 13 | 2020 | 1100 | 1.180 |
Why?
| Animals | 26 | 2024 | 13150 | 1.070 |
Why?
| Epstein-Barr Virus Infections | 3 | 2022 | 31 | 1.020 |
Why?
| Cell Proliferation | 10 | 2021 | 1007 | 0.990 |
Why?
| Cell Transformation, Viral | 2 | 2016 | 25 | 0.990 |
Why?
| Mice | 17 | 2024 | 5720 | 0.970 |
Why?
| Interleukin-10 | 2 | 2018 | 84 | 0.970 |
Why?
| Biological Therapy | 1 | 2024 | 16 | 0.940 |
Why?
| Histamine | 2 | 2023 | 25 | 0.930 |
Why?
| Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.920 |
Why?
| Anus Neoplasms | 1 | 2024 | 24 | 0.920 |
Why?
| Bacterial Proteins | 2 | 2020 | 373 | 0.890 |
Why?
| Echinomycin | 1 | 2023 | 6 | 0.890 |
Why?
| Virus Diseases | 1 | 2024 | 40 | 0.890 |
Why?
| Cough | 1 | 2023 | 54 | 0.890 |
Why?
| Penile Neoplasms | 1 | 2024 | 45 | 0.890 |
Why?
| Interferon Type I | 1 | 2023 | 25 | 0.870 |
Why?
| Herpesviridae | 2 | 2022 | 17 | 0.870 |
Why?
| Porphyromonas gingivalis | 2 | 2020 | 16 | 0.840 |
Why?
| Nuclear Proteins | 5 | 2023 | 243 | 0.840 |
Why?
| Mycoses | 1 | 2023 | 158 | 0.830 |
Why?
| Human Umbilical Vein Endothelial Cells | 4 | 2019 | 90 | 0.830 |
Why?
| Small Cell Lung Carcinoma | 1 | 2022 | 26 | 0.800 |
Why?
| Sphingolipids | 2 | 2020 | 15 | 0.780 |
Why?
| Schistosoma japonicum | 2 | 2018 | 2 | 0.780 |
Why?
| RNA, Viral | 4 | 2022 | 125 | 0.770 |
Why?
| Eukaryotic Initiation Factor-4G | 1 | 2021 | 4 | 0.770 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2021 | 210 | 0.760 |
Why?
| Cell Line | 9 | 2021 | 1002 | 0.740 |
Why?
| Brain Stem Neoplasms | 1 | 2020 | 4 | 0.720 |
Why?
| Antigens, Viral | 4 | 2016 | 44 | 0.720 |
Why?
| Antigens, Bacterial | 1 | 2020 | 55 | 0.720 |
Why?
| Drug Resistance, Neoplasm | 3 | 2019 | 308 | 0.720 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 107 | 0.710 |
Why?
| Tumor Virus Infections | 1 | 2019 | 43 | 0.700 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 4 | 0.690 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 69 | 0.690 |
Why?
| Hepatocyte Growth Factor | 2 | 2016 | 9 | 0.680 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 38 | 0.670 |
Why?
| Virus Replication | 5 | 2020 | 140 | 0.670 |
Why?
| Helminth Proteins | 1 | 2018 | 2 | 0.650 |
Why?
| Antigens, Helminth | 1 | 2018 | 4 | 0.650 |
Why?
| Antibodies, Antinuclear | 1 | 2018 | 14 | 0.650 |
Why?
| Antibodies, Protozoan | 1 | 2018 | 12 | 0.640 |
Why?
| 4-Butyrolactone | 1 | 2018 | 5 | 0.640 |
Why?
| Endothelium, Vascular | 3 | 2016 | 254 | 0.640 |
Why?
| Interleukin-12 | 1 | 2018 | 31 | 0.640 |
Why?
| Interleukin-17 | 1 | 2018 | 36 | 0.630 |
Why?
| Mycobacterium tuberculosis | 1 | 2020 | 280 | 0.630 |
Why?
| Quorum Sensing | 1 | 2018 | 8 | 0.630 |
Why?
| Fibroblasts | 4 | 2016 | 343 | 0.630 |
Why?
| Hyaluronic Acid | 2 | 2015 | 34 | 0.610 |
Why?
| Transcriptional Activation | 1 | 2018 | 122 | 0.610 |
Why?
| Quinolones | 1 | 2018 | 39 | 0.610 |
Why?
| Tumor Microenvironment | 2 | 2016 | 210 | 0.600 |
Why?
| Papillomavirus E7 Proteins | 1 | 2017 | 31 | 0.590 |
Why?
| Tumor Cells, Cultured | 4 | 2020 | 465 | 0.590 |
Why?
| Oncogene Proteins, Viral | 1 | 2017 | 52 | 0.570 |
Why?
| Mice, SCID | 5 | 2020 | 175 | 0.570 |
Why?
| Male | 19 | 2024 | 25093 | 0.560 |
Why?
| Herpesvirus 4, Human | 3 | 2022 | 35 | 0.560 |
Why?
| Trans-Activators | 2 | 2020 | 134 | 0.560 |
Why?
| Lipid Metabolism | 1 | 2017 | 175 | 0.550 |
Why?
| Heme Oxygenase-1 | 1 | 2016 | 19 | 0.540 |
Why?
| ADAM Proteins | 1 | 2016 | 20 | 0.530 |
Why?
| Repressor Proteins | 1 | 2017 | 151 | 0.530 |
Why?
| Middle Aged | 13 | 2023 | 11997 | 0.530 |
Why?
| Gene Expression Profiling | 5 | 2020 | 1031 | 0.500 |
Why?
| Piperidines | 1 | 2015 | 97 | 0.500 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 54 | 0.490 |
Why?
| Teichoic Acids | 1 | 2014 | 7 | 0.480 |
Why?
| Virus Internalization | 1 | 2014 | 17 | 0.480 |
Why?
| Lymphoma, AIDS-Related | 1 | 2014 | 16 | 0.480 |
Why?
| Up-Regulation | 6 | 2020 | 450 | 0.470 |
Why?
| Female | 16 | 2024 | 26329 | 0.460 |
Why?
| Endothelial Cells | 4 | 2024 | 269 | 0.460 |
Why?
| Cell Cycle Checkpoints | 3 | 2020 | 32 | 0.460 |
Why?
| Mice, Inbred NOD | 4 | 2020 | 96 | 0.450 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 595 | 0.450 |
Why?
| Lipopolysaccharides | 1 | 2014 | 191 | 0.440 |
Why?
| Cell Survival | 4 | 2021 | 598 | 0.440 |
Why?
| Dual Specificity Phosphatase 1 | 1 | 2012 | 9 | 0.430 |
Why?
| Staphylococcus epidermidis | 1 | 2012 | 11 | 0.420 |
Why?
| Catheters, Indwelling | 1 | 2012 | 58 | 0.410 |
Why?
| Antineoplastic Agents | 2 | 2019 | 1172 | 0.410 |
Why?
| Receptors, Histamine | 2 | 2023 | 7 | 0.400 |
Why?
| Cells, Cultured | 4 | 2020 | 1571 | 0.400 |
Why?
| Neoplasm Invasiveness | 5 | 2019 | 268 | 0.400 |
Why?
| Adult | 10 | 2020 | 13160 | 0.400 |
Why?
| Young Adult | 5 | 2020 | 3936 | 0.390 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2011 | 4 | 0.380 |
Why?
| Autoantigens | 2 | 2023 | 58 | 0.380 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 188 | 0.370 |
Why?
| Cell Cycle Proteins | 2 | 2023 | 166 | 0.370 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2011 | 156 | 0.370 |
Why?
| Monocytes | 2 | 2017 | 132 | 0.370 |
Why?
| Biofilms | 1 | 2012 | 180 | 0.370 |
Why?
| Macrophages | 2 | 2010 | 364 | 0.360 |
Why?
| Interferons | 2 | 2023 | 40 | 0.360 |
Why?
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2010 | 4 | 0.360 |
Why?
| Cell Movement | 5 | 2020 | 247 | 0.350 |
Why?
| High-Throughput Screening Assays | 2 | 2020 | 37 | 0.350 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2010 | 50 | 0.350 |
Why?
| Epithelial-Mesenchymal Transition | 3 | 2019 | 47 | 0.350 |
Why?
| RNA Interference | 5 | 2016 | 179 | 0.350 |
Why?
| Immunoblotting | 3 | 2015 | 118 | 0.340 |
Why?
| Blotting, Western | 3 | 2017 | 602 | 0.330 |
Why?
| Down-Regulation | 3 | 2017 | 349 | 0.320 |
Why?
| Staphylococcus aureus | 3 | 2020 | 326 | 0.320 |
Why?
| Interleukin-6 | 1 | 2010 | 264 | 0.310 |
Why?
| RNA, Messenger | 4 | 2017 | 1105 | 0.310 |
Why?
| Disease Progression | 4 | 2021 | 822 | 0.300 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 108 | 0.300 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 115 | 0.300 |
Why?
| Hypertension | 2 | 2024 | 532 | 0.300 |
Why?
| HIV | 2 | 2019 | 24 | 0.300 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 181 | 0.290 |
Why?
| Transcription Factors | 2 | 2023 | 563 | 0.290 |
Why?
| Virulence Factors | 2 | 2020 | 78 | 0.270 |
Why?
| RNA, Small Interfering | 2 | 2016 | 215 | 0.260 |
Why?
| Oxidative Stress | 1 | 2010 | 768 | 0.260 |
Why?
| Cell Transformation, Neoplastic | 2 | 2023 | 177 | 0.250 |
Why?
| Aged | 5 | 2020 | 9272 | 0.250 |
Why?
| Mice, Nude | 4 | 2020 | 252 | 0.250 |
Why?
| Interferon-gamma | 2 | 2023 | 174 | 0.250 |
Why?
| Disease Models, Animal | 3 | 2022 | 1451 | 0.250 |
Why?
| MAP Kinase Signaling System | 2 | 2015 | 118 | 0.240 |
Why?
| Oncogene Proteins | 1 | 2024 | 17 | 0.240 |
Why?
| Endothelium, Lymphatic | 1 | 2024 | 11 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 412 | 0.230 |
Why?
| DNA Damage | 2 | 2016 | 301 | 0.230 |
Why?
| Phosphorylation | 2 | 2017 | 536 | 0.230 |
Why?
| Immunocompromised Host | 2 | 2015 | 120 | 0.230 |
Why?
| Cytokines | 2 | 2017 | 612 | 0.230 |
Why?
| Immunohistochemistry | 2 | 2021 | 971 | 0.230 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 17 | 0.220 |
Why?
| Polymerase Chain Reaction | 3 | 2015 | 455 | 0.220 |
Why?
| Interferon-alpha | 1 | 2023 | 47 | 0.220 |
Why?
| DNA Repair | 1 | 2024 | 192 | 0.210 |
Why?
| Ultrasonography, Interventional | 1 | 2023 | 135 | 0.210 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2023 | 53 | 0.210 |
Why?
| Tubercidin | 1 | 2022 | 3 | 0.210 |
Why?
| Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.210 |
Why?
| Phenanthridines | 1 | 2022 | 4 | 0.210 |
Why?
| Transaminases | 1 | 2022 | 11 | 0.210 |
Why?
| Adenosine Monophosphate | 1 | 2022 | 15 | 0.200 |
Why?
| Alanine | 1 | 2022 | 42 | 0.200 |
Why?
| Cell Cycle | 1 | 2023 | 232 | 0.200 |
Why?
| Benzamidines | 1 | 2021 | 5 | 0.200 |
Why?
| Azithromycin | 1 | 2021 | 25 | 0.200 |
Why?
| Lymph Nodes | 1 | 2023 | 264 | 0.190 |
Why?
| Transfection | 2 | 2014 | 357 | 0.190 |
Why?
| HEK293 Cells | 2 | 2019 | 222 | 0.190 |
Why?
| Guanidines | 1 | 2021 | 31 | 0.190 |
Why?
| Structure-Activity Relationship | 2 | 2020 | 394 | 0.190 |
Why?
| Neoplasm Transplantation | 3 | 2019 | 85 | 0.190 |
Why?
| Immune Evasion | 1 | 2021 | 11 | 0.190 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2021 | 62 | 0.190 |
Why?
| Ubiquitin | 1 | 2020 | 45 | 0.190 |
Why?
| Bacteroidaceae Infections | 1 | 2020 | 4 | 0.180 |
Why?
| Interleukin-1 | 1 | 2020 | 104 | 0.180 |
Why?
| Immunotherapy | 1 | 2022 | 238 | 0.180 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2020 | 136 | 0.170 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 245 | 0.170 |
Why?
| Tumor Escape | 1 | 2019 | 16 | 0.170 |
Why?
| Carcinoma, Renal Cell | 1 | 2020 | 106 | 0.170 |
Why?
| Drug Evaluation, Preclinical | 1 | 2019 | 144 | 0.170 |
Why?
| Molecular Structure | 1 | 2020 | 297 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 2 | 2020 | 1374 | 0.160 |
Why?
| Homeodomain Proteins | 1 | 2019 | 80 | 0.160 |
Why?
| Interleukin-1beta | 1 | 2019 | 75 | 0.160 |
Why?
| Kidney Neoplasms | 1 | 2020 | 178 | 0.160 |
Why?
| Bacterial Load | 1 | 2018 | 12 | 0.160 |
Why?
| Autoimmunity | 1 | 2018 | 35 | 0.160 |
Why?
| HIV-1 | 1 | 2018 | 55 | 0.160 |
Why?
| Transplantation, Heterologous | 2 | 2019 | 74 | 0.160 |
Why?
| Pseudomonas Infections | 1 | 2018 | 48 | 0.160 |
Why?
| Neovascularization, Pathologic | 1 | 2019 | 161 | 0.160 |
Why?
| Cell Growth Processes | 1 | 2018 | 22 | 0.160 |
Why?
| Pseudomonas aeruginosa | 1 | 2018 | 72 | 0.150 |
Why?
| Virulence | 1 | 2018 | 171 | 0.150 |
Why?
| Microscopy, Electron | 1 | 2017 | 77 | 0.150 |
Why?
| Pandemics | 1 | 2022 | 554 | 0.150 |
Why?
| Sphingosine | 2 | 2015 | 26 | 0.150 |
Why?
| Lysophospholipids | 2 | 2015 | 34 | 0.150 |
Why?
| Random Allocation | 1 | 2018 | 280 | 0.150 |
Why?
| Toll-Like Receptor 2 | 1 | 2017 | 24 | 0.140 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2018 | 163 | 0.140 |
Why?
| Exons | 1 | 2017 | 95 | 0.140 |
Why?
| Exoribonucleases | 1 | 2016 | 2 | 0.140 |
Why?
| Exonucleases | 1 | 2016 | 5 | 0.140 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 48 | 0.140 |
Why?
| Lung | 1 | 2020 | 480 | 0.140 |
Why?
| Pleural Effusion | 1 | 2017 | 38 | 0.140 |
Why?
| Ubiquitins | 1 | 2016 | 39 | 0.140 |
Why?
| Tuberculosis, Pulmonary | 1 | 2017 | 103 | 0.140 |
Why?
| Protoporphyrins | 1 | 2016 | 5 | 0.140 |
Why?
| Receptors, Cell Surface | 1 | 2017 | 121 | 0.140 |
Why?
| Metalloporphyrins | 1 | 2016 | 7 | 0.140 |
Why?
| Autophagy | 1 | 2017 | 168 | 0.130 |
Why?
| Molluscacides | 1 | 2015 | 1 | 0.130 |
Why?
| Salicylanilides | 1 | 2015 | 1 | 0.130 |
Why?
| Gastropoda | 1 | 2015 | 2 | 0.130 |
Why?
| Comet Assay | 1 | 2015 | 9 | 0.130 |
Why?
| Protein Kinase Inhibitors | 1 | 2018 | 202 | 0.130 |
Why?
| Anthelmintics | 1 | 2015 | 8 | 0.130 |
Why?
| Base Sequence | 1 | 2017 | 650 | 0.130 |
Why?
| Membrane Proteins | 1 | 2018 | 342 | 0.130 |
Why?
| Amino Acid Sequence | 1 | 2017 | 587 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 169 | 0.130 |
Why?
| Necrosis | 1 | 2016 | 177 | 0.130 |
Why?
| Oxidoreductases | 1 | 2015 | 57 | 0.130 |
Why?
| Nerve Tissue Proteins | 1 | 2017 | 193 | 0.130 |
Why?
| Cohort Studies | 1 | 2019 | 1422 | 0.130 |
Why?
| Transcriptome | 1 | 2017 | 313 | 0.120 |
Why?
| Pyrazoles | 1 | 2015 | 113 | 0.120 |
Why?
| Mice, Inbred BALB C | 3 | 2020 | 303 | 0.120 |
Why?
| Glutamates | 1 | 2014 | 21 | 0.120 |
Why?
| Cystine | 1 | 2014 | 11 | 0.120 |
Why?
| Lymphocytes | 2 | 2017 | 151 | 0.120 |
Why?
| Glucuronosyltransferase | 1 | 2015 | 126 | 0.120 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 987 | 0.110 |
Why?
| Sodium Chloride, Dietary | 2 | 2024 | 33 | 0.110 |
Why?
| Flow Cytometry | 1 | 2015 | 470 | 0.110 |
Why?
| Sodium | 2 | 2024 | 92 | 0.110 |
Why?
| Molecular Targeted Therapy | 1 | 2013 | 119 | 0.110 |
Why?
| Bacteriolysis | 1 | 2012 | 2 | 0.110 |
Why?
| NF-kappa B | 1 | 2014 | 314 | 0.110 |
Why?
| Bacterial Adhesion | 1 | 2012 | 15 | 0.110 |
Why?
| RNA, Bacterial | 1 | 2012 | 55 | 0.100 |
Why?
| Reactive Oxygen Species | 1 | 2014 | 408 | 0.100 |
Why?
| Mouth Neoplasms | 1 | 2011 | 20 | 0.100 |
Why?
| DNA, Bacterial | 1 | 2012 | 185 | 0.100 |
Why?
| Cross Infection | 1 | 2012 | 95 | 0.100 |
Why?
| Bacteremia | 1 | 2012 | 92 | 0.100 |
Why?
| Aged, 80 and over | 1 | 2018 | 3125 | 0.090 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2011 | 201 | 0.090 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2010 | 5 | 0.090 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 23 | 0.090 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2010 | 12 | 0.090 |
Why?
| Reactive Nitrogen Species | 1 | 2010 | 22 | 0.090 |
Why?
| Cell Adhesion | 1 | 2010 | 158 | 0.090 |
Why?
| 3' Untranslated Regions | 1 | 2010 | 52 | 0.090 |
Why?
| Protein Isoforms | 1 | 2010 | 119 | 0.090 |
Why?
| Staphylococcal Infections | 1 | 2012 | 269 | 0.090 |
Why?
| Neoplasm Metastasis | 2 | 2020 | 231 | 0.080 |
Why?
| Neoplasm Staging | 1 | 2010 | 746 | 0.070 |
Why?
| Adolescent | 1 | 2018 | 6340 | 0.070 |
Why?
| Child | 1 | 2018 | 6824 | 0.070 |
Why?
| Protein Binding | 2 | 2020 | 660 | 0.070 |
Why?
| Receptors, Purinergic P2X7 | 1 | 2024 | 9 | 0.060 |
Why?
| Receptors, Interleukin-1 | 1 | 2022 | 17 | 0.050 |
Why?
| Adaptive Immunity | 1 | 2022 | 31 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2024 | 234 | 0.050 |
Why?
| Sodium Chloride Symporters | 1 | 2022 | 7 | 0.050 |
Why?
| Kidney Tubules, Distal | 1 | 2022 | 14 | 0.050 |
Why?
| Mice, Knockout | 1 | 2024 | 841 | 0.050 |
Why?
| Neovascularization, Physiologic | 1 | 2021 | 67 | 0.050 |
Why?
| Genome, Viral | 1 | 2020 | 79 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2021 | 406 | 0.040 |
Why?
| Phenotype | 2 | 2014 | 727 | 0.040 |
Why?
| Vimentin | 1 | 2019 | 32 | 0.040 |
Why?
| Cadherins | 1 | 2019 | 68 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 2018 | 32 | 0.040 |
Why?
| Bacterial Translocation | 1 | 2018 | 16 | 0.040 |
Why?
| Survival Rate | 1 | 2021 | 905 | 0.040 |
Why?
| Mice, Inbred C57BL | 1 | 2024 | 1806 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 477 | 0.040 |
Why?
| Oxygen | 1 | 2020 | 325 | 0.040 |
Why?
| Niclosamide | 1 | 2015 | 1 | 0.030 |
Why?
| Parasitic Sensitivity Tests | 1 | 2015 | 2 | 0.030 |
Why?
| Prognosis | 1 | 2021 | 1952 | 0.030 |
Why?
| Acetylcholinesterase | 1 | 2015 | 19 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2015 | 65 | 0.030 |
Why?
| Inhibitory Concentration 50 | 1 | 2015 | 76 | 0.030 |
Why?
| Esters | 1 | 2015 | 22 | 0.030 |
Why?
| Nitric Oxide Synthase | 1 | 2015 | 75 | 0.030 |
Why?
| Zebrafish | 1 | 2015 | 54 | 0.030 |
Why?
| Case-Control Studies | 1 | 2018 | 1128 | 0.030 |
Why?
| Mutation | 1 | 2020 | 1293 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2014 | 61 | 0.030 |
Why?
| Monocarboxylic Acid Transporters | 1 | 2014 | 2 | 0.030 |
Why?
| Membrane Microdomains | 1 | 2014 | 12 | 0.030 |
Why?
| Vesicular Transport Proteins | 1 | 2014 | 35 | 0.030 |
Why?
| Molecular Typing | 1 | 2012 | 10 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2012 | 39 | 0.030 |
Why?
| China | 1 | 2012 | 87 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 271 | 0.020 |
Why?
| Genotype | 1 | 2012 | 538 | 0.020 |
Why?
| Enzyme Activation | 1 | 2011 | 276 | 0.020 |
Why?
| Hospitals | 1 | 2012 | 175 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 157 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 141 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 743 | 0.020 |
Why?
|
|
Qin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|